Trials / Completed
CompletedNCT05129657
CSD201001: Study to Assess Elements of Abuse Liability for Three Nicotine Pouches
An In-Clinic Confinement Study to Assess Elements of Abuse Liability for Three P10 Nicotine Pouches
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- RAI Services Company · Industry
- Sex
- All
- Age
- 21 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This is a two-site, open-label, randomized, 5-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics \[PD\]) and plasma nicotine uptake (pharmacokinetics \[PK\]) during and following ad libitum use of the study investigational products (IPs) by generally healthy smokers.
Detailed description
Cigarette smokers and smokers also using smokeless tobacco products (ST) will be recruited into this AL study to evaluate elements of AL of three nicotine pouches compared to combustible cigarettes (CC) and nicotine polacrilex gum. At least one-third of the study population will include smokers who also use ST. Potential subjects may complete a pre-screening telephone interview. Subjects will complete a Screening Visit to assess their eligibility within 45 days prior to check-in and enrollment. Starting on Day 1, subjects will check-in at the clinical site to complete procedures to confirm eligibility. Eligible subjects will be enrolled and confined for 6 days. Subjects will be randomized to one of 10 product use sequences (using a Williams Design) in which the subjects will evaluate one IP in each of five separate Test Sessions, such that each subject will evaluate five IPs, including three IPs, and both a high-AL comparator (subject's usual brand \[UB\] cigarette) and a low-AL comparator (a commercially available nicotine replacement therapy \[NRT\] nicotine gum). On Day 2 and continuing through Day 6, subjects will participate in Test Sessions that will last for approximately 4 hours. Each Test Session will include collection of both PD measures (subjective and physiological) and PK measures prior to, during, and following IP use. On the half day prior to each respective Test Session, a Product Acclimation Period will allow subjects ad libitum use of the randomized IP (at least two trial uses) for product familiarization prior to use in the next day's Test Session. Subjects can also use their UB cigarettes ad libitum, until the 12-hour tobacco abstinence begins prior to each Test Session, as long as the minimum use requirement for randomized IP is met.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Product A | Usual Brand (UB) filtered, non-menthol or menthol cigarette |
| OTHER | Product B | P1012914, A nicotine pouch product with 4 mg of nicotine |
| OTHER | Product C | P1012915, A nicotine pouch product with 8 mg of nicotine |
| OTHER | Product D | P1012919, A nicotine pouch product with 12 mg of nicotine |
| OTHER | Product N | Nicorette® White Ice Mint 4 mg nicotine gum |
Timeline
- Start date
- 2021-11-02
- Primary completion
- 2022-06-24
- Completion
- 2022-06-24
- First posted
- 2021-11-22
- Last updated
- 2024-04-30
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05129657. Inclusion in this directory is not an endorsement.